{
    "id": 29083,
    "fullName": "RCSD1 - ABL1",
    "impact": "fusion",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "RCSD1-ABL1 results from the fusion of RCSD1 and ABL1 (PMID: 19794096). RCSD1-ABL1 has been identified in pre-B lymphoblastic leukemia (PMID: 19794096), but has not been biochemically characterized and therefore, the effect on protein function is unknown (PubMed, Oct 2019).",
            "references": [
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 13167,
                    "pubMedId": 19794096,
                    "title": "A novel dasatinib-sensitive RCSD1-ABL1 fusion transcript in chemotherapy-refractory adult pre-B lymphoblastic leukemia with t(1;9)(q24;q34).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19794096"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 92241,
        "geneSymbol": "RCSD1",
        "terms": [
            "RCSD1",
            "CAPZIP",
            "MK2S4"
        ]
    },
    "variant": "RCSD1 - ABL1",
    "createDate": "12/09/2018",
    "updateDate": "10/17/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 25,
                "geneSymbol": "ABL1",
                "terms": [
                    "ABL1",
                    "ABL",
                    "BCR-ABL",
                    "bcr/abl",
                    "c-ABL",
                    "c-ABL1",
                    "CHDSKM",
                    "JTK7",
                    "p150",
                    "v-abl"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 15410,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Gleevec (imatinib mesylate) treatment resulted in remission greater than eleven years in a pediatric patient with refractory B-cell precursor acute lymphoblastic leukemia harboring an RCSD1-ABL1 fusion (PMID: 27125982).",
            "molecularProfile": {
                "id": 31012,
                "profileName": "RCSD1 - ABL1"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 80146,
                "name": "childhood B-cell acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13168,
                    "pubMedId": 27125982,
                    "title": "Imatinib-induced long-term remission in a relapsed RCSD1-ABL1-positive acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27125982"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15409,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a chemotherapy-refractory patient with pre-B acute lymphoblastic leukemia harboring an RCSD1-ABL1 fusion demonstrated a complete cytogenetic response following treatment with Sprycel (dasatinib), which was maintained for greater than nine months on Sprycel (dasatinib) monotherapy (PMID: 19794096).",
            "molecularProfile": {
                "id": 31012,
                "profileName": "RCSD1 - ABL1"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13167,
                    "pubMedId": 19794096,
                    "title": "A novel dasatinib-sensitive RCSD1-ABL1 fusion transcript in chemotherapy-refractory adult pre-B lymphoblastic leukemia with t(1;9)(q24;q34).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19794096"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19546,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Gleevec (imatinib mesylate) and Sprycel (dasatinib) co-administered with dexamethasone resulted in transient clinical benefit in a patient with B-cell acute lymphoblastic leukemia harboring RCSD1-ABL1, but the disease became refractory after subsequent acquirement of chromosomal translocations including t(5;16)(q33;q24), dic(18;20)(p11.2;q11.2), and t(10;19)(q24;p13.3) (PMID: 21863287).",
            "molecularProfile": {
                "id": 31012,
                "profileName": "RCSD1 - ABL1"
            },
            "therapy": {
                "id": 9065,
                "therapyName": "Dasatinib + Dexamethasone + Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 60592,
                "name": "B-cell adult acute lymphocytic leukemia",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 17171,
                    "pubMedId": 21863287,
                    "title": "RCSD1-ABL1-positive B lymphoblastic leukemia is sensitive to dexamethasone and tyrosine kinase inhibitors and rapidly evolves clonally by chromosomal translocations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21863287"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "molecularProfiles": [
        {
            "id": 31012,
            "profileName": "RCSD1 - ABL1",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}